Management of reactive arthritis

Bibliography

• TOIVANEN A, TOIVANEN P: Reactive arthritis. Carr: Opin. Rheumatol. (2000) 12(4):300–305.
   PubMedGoogle Scholar
• DOUGADOS M, VAN DER LINDEN S, JUHLIN R et al.: The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritic Rheum. (1991) 34(10):1218–1227.
   Google Scholar
• FL ORES D, MARQUEZ J, GARZA M, ESPINOZA LR: Reactive arthritis: newer developments. Rheum. Dis. Clin. North Am. (2003) 29(1):37–59.
   PubMedGoogle Scholar
• •A good review of latest developments in the ReA field.
   Google Scholar
• LEIRISALO-REPO M: Enteric infectionsand arthritis: clinical aspects. In: The Spondyloarthritides. Calm A, Taurog JD (Eds), Oxford University Press, Oxford, UK (1998):59.
   Google Scholar
• CUSH JJ, LIPSKY PE: Reiter's syndromeand reactive arthritis. In: Arthritic and allied conditions (14th edit). Koopman WJ (Ed.), Lippincott Williams & Wilkins, Philadelphia, USA (2001):1324–1344.
   Google Scholar
• •A complete overview of all clinical aspects of ReA.
   Google Scholar
• BRAUN J, KINGSLEY G, VAN DER HEIJDE D, SIEPER J: On the difficulties of establishing a consensus on the definition of and diagnostic investigation for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritic, Berlin, Germany, July 3 —6, 1999. Rheumatol. (2000) 27(9):2185–2192.
   Google Scholar
• ••A very interesting article that outlines thedisagreement existing among many experts about several aspects of ReA.
   Google Scholar
• OLIVIERI I, BAROZZI L, FAVARO L et al.: Dactylitis in patients with seronegative spondylarthropathy. Assessment by ultrasonography and magnetic resonance imaging. Arthritis Rheum. (1996) 39(9):1524–1528.
   Google Scholar
• ••A complete analysis of clinical and instrumental approach to dactylitis.
   Google Scholar
• OLIVIERI I, BAROZZI L, PIERRO A, DE MATTEIS M, PADULA A, PAVLICA P: Toe dactylitis in patients with spondyloarthropathy: assessment by magnetic resonance imaging. Rheumatol. (1997) 24(5):926–930.
   Google Scholar
• PALAZZI C, D'AMICO E, IZZO F, PACE-PALITTI V, PETRICCA A: Ureaplasma urealyticum as a possible cause of reflex sympathetic dystrophy syndrome. Scand. Rheumatol. (2002) 31(2):97–99.
   PubMedGoogle Scholar
• BERGFELDT L: HLA-B27-associated cardiac disease. Ann. Intern. Med. (1997) 127 (8 Pt 1):621–629.
   Google Scholar
• ••An extensive review written by the principal expert in this specific field.
   Google Scholar
• MICHET CJ, MACHADO EB, BALLARD DJ et al.: Epidemiology of Reiter's syndrome in Rochester, Minnesota: 1950-1980. Arthritic Rheum. (1988) 31(3):428–431.
   PubMedGoogle Scholar
• KVIEN TK, GLENNAS A, MELBY K et al.: Reactive arthritis: incidence, triggering agents and clinical presentation. Rheumatol (1994) 21(1):115–122.
   Google Scholar
• HANNU T, MATTILA L, RAUTELIN H et al.: Campylobacter triggered reactive arthritis: a population-based study. Rheumatology (Oxford) (2002) 41(3):312–318.
   PubMedGoogle Scholar
• SODERLIN MK, BORJESSON 0, KAUTIAINEN H, SKOGH T, LEIRISALO-REPO M: Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann. Rheum. Dis. (2002) 61(10911–915.
   Google Scholar
• •A recent and interesting study that examines the incidence of different rheumatic disorders in Sweden.
   Google Scholar
• SODERLIN MK, KAUTIAINEN H, PUOLAKKAINEN M et al: Infections preceding early arthritis in southern Sweden: a prospective population-based study. J. Rheumatol (2003) 30(4):425–429.
   PubMedGoogle Scholar
• ILIOPOULOS A, KARRAS D, IOAKIMIDIS D et al.: Change in the epidemiology of Reiter's syndrome (reactive arthritis) in the post-AIDS era? An analysis of cases appearing in the Greek Army.Rheumatol (1995) 22(2):252–254.
   Google Scholar
• RABENAU H, BERGER A, DOERR HW, WEBER B: Testing for Chlamydia trachomatis in urine. Lancet (1997) 349(9057):1024–1025.
   PubMedGoogle Scholar
• GAYDOS CA, HOWELL MR, PARE B, CLARK KL, ELLIS DA, HENDRIX RM et al.: Chlamydia trachomatis infection in female military recruits. N Engl.). Med. (1998) 339(11):739–744.
   PubMed Web of Science ®Google Scholar
• VAN DYCK E, IEVEN M, PATTYN S, VAN DAMME L, LAGA M: Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by enzime immunoassay, culture, and three nucleic acid amplification tests. J. Clin. Microbiol (2001) 39(5):1751–1756.
   PubMed Web of Science ®Google Scholar
• PASTERNACK R, VUORINEN P, MIETTINEN A: Comparison of a transcription-mediated amplification assay and polymerase chain reaction for detection of Chlamydia trachomatis in first-void urine. Eur. I Clin. Microbial Infect. Dis. (1999) 18(2):142–144.
   PubMedGoogle Scholar
• FENDLER C, LAITKO S, SORENSEN H et al.: Frequency of triggering bacteria in patients with reactive arthritis and undifferentiated oligoarthritis and the importance of the tests used for diagnosis. Ann. Rheum. Dis. (2001) 60(4):337–343.
   PubMedGoogle Scholar
• HOROWITZ S, HOROWITZ J, TAYLOR-ROBINSON D et al.: Ureaplasma urealyticum in Reiter's Syndrome. Rheumatol (1994) 21(5):877–882.
   Google Scholar
• •The first report on the favourable effects of antimicrobial drugs in treatment of ReA induced by Ureaplasma.
   Google Scholar
• ERLACHER L, WINTERSBERGER W, MENSCHIK M et al.: Reactive arthritis: urogenital swab culture is the only useful diagnostic method for the detection of the arthritogenic infection in extra-articularly asymptomatic patients with undifferentiated oligoarthritis. Br. Rheumatol (1995) 34(9):838–842.
   PubMedGoogle Scholar
• DUTTA S, CHATTERJEE A, DUTTA P et al.: Sensitivity and performance of a direct PCR with stool samples in comparison to conventional techniques for diagnosis of Shigella and enteroinvasive Escherichia coli infection in children with acute diarrhoea in Calcutta, India. Med. Microbial (2001) 50(8):667–674.
   PubMedGoogle Scholar
• DELMEE M: Laboratory diagnosis of Clostridium difficile disease. Gin. Microbial Infect. (2001) 7(8):411–416.
   PubMedGoogle Scholar
• TURGEON DK, NOVICKI TJ, QUICK J et al.: Six rapid tests for direct detection of Clostridium difficile and its toxins in fecal samples compared with the fibroblast cytotoxicity assay. J. Clin. Microbiol (2003) 41(2):667–670.
   PubMed Web of Science ®Google Scholar
• TUUMINEN T, PAL OMAKI P, PAAVONEN J: The use of serological tests for the diagnosis of chlamydial infection. Microbiol Methods (2000) 42(3):265–279.
   PubMedGoogle Scholar
• VAINAS T, DE GRAAF R, STASSEN FR et al.: Chlamydia pneumoniae serology: comparing a commercial enzyme immunoassay and microimmunofluorescence test in patients with cardiovascular disease. Acta Pathol Microbiol Immunol Scand. (2003) 111(2):363–369.
   PubMedGoogle Scholar
• SCHUMACHER HR JR GIRARD HC, ARAYSSI T et al.: Lover prevalence of Chlamydia pneumoniae DNA compared with Chlamydia trachomatis DNA in synovial tissue of arthritis patients. Arthritis Rheum. (1999) 42(9):1889–1893.
   PubMedGoogle Scholar
• SCHUMACHER HR JR, ARAYSSI T, CRANE M et al.: Chlamydia trachomatis nucleic acids can be found in the synovium of some asymptomatic subjects. Arthritic Rheum. (1999) 42(6):1281–1284.
   PubMedGoogle Scholar
• •An interesting study that endeavours to critically re-evaluate the importance of PCR detection of chlarnydial NAs in joints.
   Google Scholar
• COX CJ, KEMPSELL KE, GASTON JSH: Investigation of infectious agents associated with arthritis by reverse transcription PCR of bacterial rRNA. Arthritis Res. Ther. (2003) 5(1):R1–R8.
   Google Scholar
• TOIVANEN A: Managing reactive arthritis. Rheumatology (Oxford) (2000) 39(2):117–119.
   PubMedGoogle Scholar
• ••An expert opinion on ReA therapy.
   Google Scholar
• MIELANTS H, VEYS EM, JOOS R: Sulphasalazine (Salazopyrin) in the treatment of enterogenic reactive synovitis and ankylosing spondylitis with peripheral arthritis. Gin. Rheumatol (1986) 5(1):80–83.
   Google Scholar
• ZWILLICH SH, COMER SS, LEE E. ERDMAN WA, LIPSKY PE: Treatment of the seronegative spondyloarthropathies with sulfasalazine. Rheumatol (1988) 16(Suppl.):33–39.
   Google Scholar
• TRNAVSY K, PELISKOVA Z, VACHA J: Sulphasalazine in the treatment of reactive arthritis. Scand.J. Rheumatol (1988) 67(Suppl.):76–79.
   Google Scholar
• DOUGADOS M, VAN DER LINDEN S, LEIRISALO-REPO M et al.: Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. (1995) 38(5):618–627.
   Google Scholar
• •A large European study on the role of sulfasalazine in ReA treatment.
   Google Scholar
• CLEGG DO, REDA DJ, WEISMAN MH et al.: Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. (1996) 39(12):2021–2027.
   PubMedGoogle Scholar
• •A large US study on the role of sulfasalazine in ReA treatment.
   Google Scholar
• CLEGG DO, REDA DJ, ABDELLATIF M:Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum. (1999) 42(11):2325–2239.
   PubMed Web of Science ®Google Scholar
• EGSMOSE C, HANSEN TM, ANDERSEN LS et al.: Limited effect of sulfasalazine treatment in reactive arthritis. A randomized double blind placebo controlled trial. Ann. Rheum. Dis. (1997) 56(1):32–36.
   Google Scholar
• CALIN A: A placebo-controlled cross-over study of azathioprine in Reiter's syndrome. Ann. Rheum. Dis. (1986) 45(8):653–655.
   PubMed Web of Science ®Google Scholar
• LALLY EV, HO G JR A review of methotrexate therapy in Reiter's syndrome. Sem. Arthritis Rheum. (1985) 15(2):139–145.
   PubMed Web of Science ®Google Scholar
• KIYOHARA A, TAKAMORI K, NIIZUMA N, OGAWA H: Successfull treatment of severe recurrent Reiter's syndrome with cyclosporin.j Am. Acad. Dermatol (1997) 36(3 PM:482–483.
   Google Scholar
• CARROLL GJ, MA DT: Effective control of incomplete reactive arthritis with cyclosporin. Rheumatology (Oxford) (2001) 40(8)945–947.
   Google Scholar
• TOIVANEN A: Bacteria-triggered reactive arthritis. Implications for antibacterial treatment. Drugs (2001) 61(3):343–351.
   Google Scholar
• ••A complete review on antibacterialtreatment of ReA.
   Google Scholar
• YU D, KUIPERS JG: Role of bacteria and HLA-B27 in the pathogenesis of reactive arthritis. Rheum. Dis. Clin. North Am. (2003) 29 (1):21–36.
   PubMed Web of Science ®Google Scholar
• ••An excellent, extended, and recent analysisof the pathogenetic mechanisms of ReA.
   Google Scholar
• LEIRISALO-REPO M, HANNU T, MATTILA L: Microbial factors in spondyloarthropathies: insights from population studies. Carr. Opin. Rheumatol (2003) 15(4):408–412.
   PubMedGoogle Scholar
• PENTTINEN MA, LIU Y, GRANFORS K: The role of infection in the pathogenesis of spondyloarthopathies with special reference to human leukocyte antigen-B27. Carr. Rheumatol Rep. (2002) 4(6):518–524.
   PubMedGoogle Scholar
• LIU Y, PENTTINEN MA, GRANFORS K: Insights into the role of infection in the spondyloarthopathies. Carr. Rheumatol Rep. (2001) 3(5):428–434.
   PubMedGoogle Scholar
• TURNER MJ, COLBERT RA: HLA-B27 and pathogenesis of spondyloarthopathies. Opin. Rheumatol (2002) 14(4)367–372.
   Google Scholar
• PACHECO-TENA C, ZHANG X, STONE M, BURGOS-VARGAS R, INMAN RD: Innate immunity in host-microbial interactions: beyond B27 in the spondyloarthopathies. Can: Opin. Rheumatol (2002) 14(4):373–382.
   PubMedGoogle Scholar
• DANGORIA N, DE LAY M, KINGSBURY DJ et al: HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum. J. Biol. Chem. (2002) 277(26):23459–23468.
   PubMed Web of Science ®Google Scholar
• ••This study reveals new possiblepathogenetic mechanisms involving HLA B27 in the development of SpA.
   Google Scholar
• FURR PM, TAYLOR-ROBINSON D: Prevalence and significance of Mycoplasma hominis and Ureaplasma urealyticum in the urines of a non-venereal disease population. Epidemiol Infect. (1987) 98(3):353–359.
   PubMedGoogle Scholar
• FRYDEN A, BENGTSSON A, FOBERG U et al.: Early antibiotics treatment of reactive arthritis associated with enteric infections: clinical and serological study. Br. Med. J. (1990) 301(6764):1299–1302
   PubMedGoogle Scholar
• LAUHIO A, LEIRISALO-REPO M, LAHDEVIRTA, SAIKKU 0, REPO H: Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum. (1991) 34(1):6–14.
   PubMedGoogle Scholar
• •The first study on tetracycline treatment of ReA.
   Google Scholar
• TOIVANEN A, YLI-KERTTULA T, LUUKKAINEN R, MERILHATI-PALO R, GRANFORS K, SEPPALA J: Effect of antimicrobial treatment on chronic reactive arthritis. Gin. Exp. Rheumatol (1993) 11(3):301–307.
   PubMedGoogle Scholar
• LOCHT H, KIHLSTROM E, LINDSTROM FD: Reactive arthritis after Salmonella among medical doctors: study of an outbreak. J. Rheumatol (1994) 21(2):371–372.
   PubMedGoogle Scholar
• •An interesting study on ReA outcome, after an outbreak induced by Salmonella. Effects of antimicrobial treatment were analysed.
   Google Scholar
• MATTILA L, LEIRISALO-REPO M, PELKONEN P, KOSKIMIES S, GRANFORS K, SIITONEN A: Reactive arthritis following an outbreak of Salmonella bovismorbificans infection. Infect. (1998) 36(3):289–295.
   Google Scholar
• SIEPERJ, FENDLER C, LAITKO S et al.:No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis. Arthritis Rheum. (1999) 42(7):1386–1396.
   PubMedGoogle Scholar
• •This work evidences the possible different effects of ciprofloxacin in EA and UA.
   Google Scholar
• YLI-KERTTULA T, LUUKKAINEN R, YLI-KERTTULA U et al.: Effect on a three-month course of ciprofloxacin on the outcome of reactive arthritis. Ann. Rheum. Dis. (2000) 59(7):565–570.
   PubMedGoogle Scholar
• YLI-KERTTULA T, LUUKKAINEN R, YLI-KERTTULA U et al.: Effect on a three-month course of ciprofloxacin on the late prognosis of reactive arthritis. Ann. Rheum. Dis. (2003) 62(9):880–884.
   PubMedGoogle Scholar
• •This study outlines amelioration in late outcome of ReA due to ciprofloxacin administration despite poor effects in early stages.
   Google Scholar
• HOOGKAMP-KORSTANJE JA, MOESKER H, BRUYN GA: Ciprofloxacin versus placebo for treatment of Yersinia enterocolitica triggered reactive arthritis. Ann. Rheum. Dis. (2000) 59(11):914–917.
   PubMedGoogle Scholar
• HANNU T, MATTILA L, SIITONEN A, LEIRISALO-REPO M: Reactive arthritis following an outbreak of Salmonella typhimurium phage 193 infection. Ann. Rheum. Dis. (2002) 61(3):264–266.
   PubMedGoogle Scholar
• SMIEJA M, MACPHERSON DW, KEAN W et al: Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis. Ann. Rheum. Dis. (2001) 60(12):1088–1094.
   PubMedGoogle Scholar
• BARDIN T, ENEL C, CORNELIS F et al.: Antibiotic treatment of venereal disease and Reiter's syndrome in a Greenland population. Arthritis Rheum. (1992) 35(2):190–194.
   PubMed Web of Science ®Google Scholar
• ••The first report on the role played by someantibacterial drugs in preventing the development of ReA.
   Google Scholar
• PANAYI GS, CLARK B: Minocycline in the treatment of patients with Reiter's syndrome. Clin. Exp. Rheumatol (1989) 7(1):100–101.
   PubMedGoogle Scholar
• LAASILA K, LAASONEN L, LEIRISALO-REPO M: Antibiotic treatment and long term prognosis of reactive arthritis. Ann. Rheum. Dis. (2003) 62(7):655–658.
   PubMedGoogle Scholar
• WOLLENHAUPT J, HAMMER M, POTT HG et al.: A double blind, placebo-controlled comparison of 2 week versus 4 months treatment with doxycycline in Chlamydia-induced reactive arthritis. Arthritis Rheum. (1997) 40:S143.
   PubMedGoogle Scholar
• LAUHIO A, SORSA T, LINDY 0 et al.: The anticollagenolytic potential of lymecycline in the long-term treatment of reactive arthritis. Arthritis Rheum. (1992) 35(2):195–198.
   Google Scholar
• BEUTLER AM, HUDSON AP, WHITTUM-HUDSON JA: Chlamydia trachomatis can persist in joint tissue after antibiotic treatment in chronic Reiter's syndrome/reactive arthritis. J. Clin. Rheumatol (1997) 3(2):125–130.
   PubMedGoogle Scholar
• ••This article evidences the possiblepersistence of Chlamydia in joints despite antibiotic therapies.
   Google Scholar
• DRESES-WERRINGLOER U, PADUBRIN I, JURGENS-SAATHOFF B, HUDSON AP, ZEIDLER H, KOHLER L: Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob. Agents. Chemother: (2000) 44(12)3288–3297.
   Google Scholar
• •This report outlines that quinolones could favour chronic Chlamydia infections.
   Google Scholar
• PALAZZI C, D'AMICO E, D'AGOSTINO L et al.: Antibiogram-driven antimicrobial treatment for Ureaplasma urealyticum genitourinary infection can be effective against chronic monoarthritis. Clin. Exp. Rheum. (2001) 19(2):230–231.
   Google Scholar
• PALAZZI C, D'AMICO E, FRATELLI V, CAPANI F: Chronic arthritis after genitourinary inflammation responsive to quinolones. Clin. Rheumatol (1997) 3(2): 183–184.
   Google Scholar
• BRAUN J, BRANDT J, LISTING J, RUDWALEIT M, SIEPER J: Biologic therapies in the spondyloarthritis: new opportunities, new challenges. Curt: Opin. Rheumatol (2003) 15(4):394–407.
   PubMedGoogle Scholar
• •A complete review on treatment with TNF-a blockers in SpA.
   Google Scholar
• ZOU JX, BRAUN J, SIEPER J: Immunological basis for the use of TNFa blocking agents in ankylosing spondylitis and immunological changes during treatment. Clin. Exp. Rheum. (2002) 20\(Suppl. 28):S34–S37.
   Google Scholar
• TOUSSIROT E, WENDLING D: Recent progress in ankylosing spondylitis treatment. Expert Opin. Pharmacother: (2003) 4(1):1–12.
   PubMedGoogle Scholar
• DE VOS M: Standard and innovative therapy of inflammatory bowel disease. Clin. Exp. Rheum. (2002) 20\(Suppl. 28):595–5100.
   Google Scholar
• BRAUN J, YIN Z, SPILLER I et al: Low secretion of tumor necrosis factor alpha, but not other Thl or Th2 cytokines, by peripheral blood mononuclear cells correlate with chronicity in reactive arthritis. Arthritic Rheum. (1999) 42 (10) :2039–2044.
   PubMedGoogle Scholar
• TUOKKO J, KOSKINEN S, WESTMAN P, YLI-KERTTULA U, TOIVANEN A, ILONEN J: Tumor necrosis factor microsatellites in reactive arthritis. Br. J. Rheumatol (1998) 37(11):1203–1206.
   PubMedGoogle Scholar
• MEADOR RJ, HSIA EC, KITUMNUAYPONG T, SCHUMACHER HR: TNF involvement and anti-TNF therapy of reactive and unclassified arthritis. Clin. Exp. Rheum. (2002) 20\(Suppl. 28):S130–S134.
   Google Scholar
• •The first report on etanercept administration in ReA.
   Google Scholar
• MEADOR RJ, HSIA EC, KITUMNUAYPONG T, SCHUMACHER HR: Is etanercept (Enbrel) effective in the treatment of reactive and undifferentiated arthritis? Arthritis Rheum. (2001) 44(Suppl.):S348 (Abstract).
   Google Scholar
• KAIPIAINEN-SEPPANEN 0, NIINISALO H, KORPILAHDE T, VIROLAINEN J: Treatment of reactive arthritis with infliximab. Scand. Rheumatol (2003) 32(2):122–124.
   PubMed Web of Science ®Google Scholar
• •The first report on inflizimab treatment of ReA.
   Google Scholar
• SALVARANI C, CANTINI F, OLIVIERI I: Disease-modifying antirheumatic drug therapy for psoriatic arthritis. Clin. Exp. Rheum. (2002) 20\(Suppl. 28):571–575.
   Google Scholar
• DRESES-VVERRINGLOER U, PADUBRIN I, ZEIDLER H, KOHLER L: Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. Antimicrob. Agents. Chemother. (2001) 45(11):3001–3008.
   PubMedGoogle Scholar
• WOLF F, MALINVERNI R: Effect of azithtromycin plus rifampin versus that azithtromycin alone in the eradication of Chlamydia pneumoniae from lung tissue in experimental pneumonitis. Antimicrob. Agents. Chemother. (1999) 43(6):1491–1493.
   PubMedGoogle Scholar
• FREIDANK HM, LOSCH P, VOGELE H, WIEDMANN-AL-AHMAD M: In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations. Antimicrob. Agents. Chemother: (1999) 43(7):1808–1810.
   PubMedGoogle Scholar
• GASTON GSH, KVIEN TK, BARDIN TH et al.: Three-month treatment of reactive arthritis with azithromycin: a EULAR double-blind, placebo-controlled study. Arthritis Rheum. (2002) 46(Suppl.):S571 (Abstract).
   Google Scholar